$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Latest from other desks

tml.the modern leap
Health / Public Health

Ziltivekimab Cuts Inflammation Markers Without Cutting Heart Events

In 6,376 patients, the IL-6 antibody beat placebo by 76 points on one marker and 64 on another, then tied it 17.6 to 17.7 on heart attacks, strokes and cardiovascular deaths.

TML Health DeskNov 22, 10:26 AM ET · 2 min read
A self-injection pen of the kind used for monthly biologic medicines. Image: Healthline Media, via rvohealth.io.
Summary

The markers moved. The disease didn't. ZEUS is the trial that separates those two sentences.

Tap a passage. React to the part that matters.

Ziltivekimab cut two inflammation markers sharply in the ZEUS trial and didn't reduce heart attacks, strokes or cardiovascular deaths at all.

ZEUS was a large, careful test of a popular idea. The trial enrolled 6,376 adults who had atherosclerotic cardiovascular disease, chronic kidney disease, and blood levels of high-sensitivity C-reactive protein at or above 2 milligrams per liter, a standard marker of cardiovascular inflammation. Half received ziltivekimab, a monoclonal antibody that blocks interleukin-6, as a 15 milligram injection under the skin once a month. Half received a matching placebo. The trial was randomized, double-blind and placebo-controlled, and it's published in The New England Journal of Medicine, with Paul Ridker as lead author.

On the blood tests, the drug did exactly what it was built to do. At 24 months, the difference between the groups in median percent change was 76 percentage points for free interleukin-6 and 64 percentage points for high-sensitivity C-reactive protein, both in ziltivekimab's favor. If the trial had been graded on biomarkers, it would have been a rout.

It was graded on events. Over a median follow-up of 33 months, the primary outcome, a composite of cardiovascular death, nonfatal heart attack and nonfatal stroke, occurred in 561 patients on ziltivekimab, 17.6 percent, and 565 patients on placebo, 17.7 percent. The hazard ratio was 0.99, with a P value of 0.84. In plain terms, the two lines sit on top of each other.

The safety ledger leans the wrong way. Overall serious adverse events were nearly identical, 54.6 percent on the drug and 54.8 percent on placebo. Serious infections weren't: 20.4 percent of patients on ziltivekimab had one, against 17.9 percent on placebo. Suppressing interleukin-6 is suppressing part of the immune system, and the infection gap is the cost side of that trade showing up in the data.

The limits of the result deserve the same care as the result itself. ZEUS tested one drug, one dose and one population: patients who already had cardiovascular disease and kidney disease, with inflammation confirmed by a blood test. It doesn't rule out benefit in other groups, and it doesn't settle whether interleukin-6 matters earlier in the disease. What it does settle is narrower and, for prescribing, more useful. In this population, over nearly three years, driving these two markers down didn't prevent the events the markers are supposed to predict.

That distinction is the story. A biomarker can move because a drug touches it, and touching it isn't the same as changing the disease. ZEUS is now the reference point any inflammation-based prevention claim has to answer, because it's the trial that measured the events instead of the markers.

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.